Key result
Carvedilol significantly reduced systolic blood pressure by 24.6 mmHg and diastolic blood pressure by 12.1 mmHg from baseline over 18 months in Japanese patients with hypertension.
Why the study?
Does carvedilol improve blood pressure and maintain safety in hypertensive patients in Japan?
Cohort (n=380)
Yes
Does carvedilol improve blood pressure and maintain safety in hypertensive patients in Japan?
Long-term carvedilol treatment in Japanese hypertensive patients significantly reduced blood pressure without adversely affecting fasting plasma glucose or causing significant safety concerns.
Answers are grounded in this paper and cite their sources.
Carvedilol was associated with sustained BP reduction and metabolic safety in Japanese hypertensives; leaves open need for randomized confirmation.
Background: In Japan, when pharmaceutical companies launch a new drug, they are obligated to conduct a post-marketing survey to evaluate the safety and efficacy of the drug in accordance with Good Post-Marketing Surveillance Practice under Article 14-4 (re-examination) of the Pharmaceutical Affairs Law at contracted medical institutions. We report the results of a long-term special survey that we conducted as a post-marketing survey. Objective: The results of a prospective post-marketing survey that was conducted to assess the safety and efficacy of the b-adrenergic receptor antagonist (β-blocker) Artist® tablets 10 mg, 20mg (carvedilol) in patients with hypertension in Japan, were investigated in order to examine the safety and efficacy of the drug during long-term treatment (18 months). Patients: Patients were carvedilol-naive and had essential hypertension or renal parenchymal hypertension. Methods: We performed this survey as a prospective cohort study (special survey) utilizing a centralized registration method over 3 years (starting from April 1994), for an observation period of 18 months of carvedilol treatment. Results: Sixty-one medical institutions across Japan collected 380 case report forms of patients who received long-term administration of carvedilol, with 363 and 341 cases evaluated for safety and efficacy, respectively. The discontinuation rate was 7.2% and the incidence of adverse drug reactions was 5.23% (19 of 363) in the safety population. There was no significant change in fasting plasma glucose levels from baseline (118.1 ± 46.5mg/dL) to after carvedilol treatment (114.6 ± 43.3 mg/dL) [n = 141; p = 0.310]. In 341 evaluable patients in the efficacy population, decreases in both blood pressure and pulse rate were statistically significant at all assessment points in comparison with baseline data (p < 0.001). Similarly, in hypertensive patients with diabetes mellitus, decreases in blood pressure were statistically significant at all assessment points in comparison with baseline data (p < 0.001). Conclusions: The results of this study show that carvedilol exerted stable antihypertensive effects leading to favorable blood pressure control throughout long-term treatment, without showing any safety concerns. It was concluded that there were no clinically significant issues in terms of safety or efficacy with the long-term treatment of carvedilol in patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Iizuka et al. (2011) conducted a cohort in Essential hypertension or renal parenchymal hypertension (n=380). Carvedilol vs. Baseline was evaluated on Change in systolic blood pressure from baseline to last observation (MD -24.6, p=<0.001). Carvedilol significantly reduced systolic blood pressure by 24.6 mmHg and diastolic blood pressure by 12.1 mmHg from baseline over 18 months in Japanese patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: